Improving the efficacy of antibody-based cancer therapies
Top Cited Papers
- 1 November 2001
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 1 (2) , 118-129
- https://doi.org/10.1038/35101072
Abstract
A quarter of a century after their advent, monoclonal antibodies have become the most rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases, including cancer. Although antibodies have yet to achieve the ultimate goal of curing cancer, many innovative approaches stand poised to improve the efficacy of antibody-based therapies.Keywords
This publication has 109 references indexed in Scilit:
- Selection of tumor-specific internalizing human antibodies from phage librariesJournal of Molecular Biology, 2000
- Antibody humanization: a case of the ‘Emperor’s new clothes’?Immunology Today, 2000
- Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides 1 1Edited by I. A. WilsonJournal of Molecular Biology, 2000
- ImmunocytokinesPharmacology & Therapeutics, 1998
- Pretargeting strategies for radio-immunoguided tumour localisation and therapyEuropean Journal Of Cancer, 1997
- Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding SiteJournal of Molecular Biology, 1996
- Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display LibraryNature Biotechnology, 1996
- CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar RangeJournal of Molecular Biology, 1995
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- Replacing the complementarity-determining regions in a human antibody with those from a mouseNature, 1986